WO2023208081A1 - Substituted fluorosulfate and use thereof - Google Patents
Substituted fluorosulfate and use thereof Download PDFInfo
- Publication number
- WO2023208081A1 WO2023208081A1 PCT/CN2023/091020 CN2023091020W WO2023208081A1 WO 2023208081 A1 WO2023208081 A1 WO 2023208081A1 CN 2023091020 W CN2023091020 W CN 2023091020W WO 2023208081 A1 WO2023208081 A1 WO 2023208081A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- protein
- present application
- optionally substituted
- nucleic acid
- Prior art date
Links
- UQSQSQZYBQSBJZ-UHFFFAOYSA-M fluorosulfate group Chemical class S(=O)(=O)([O-])F UQSQSQZYBQSBJZ-UHFFFAOYSA-M 0.000 title abstract description 16
- 150000001413 amino acids Chemical class 0.000 claims abstract description 69
- 150000001875 compounds Chemical class 0.000 claims description 131
- 108090000623 proteins and genes Proteins 0.000 claims description 81
- 102000004169 proteins and genes Human genes 0.000 claims description 77
- 235000018102 proteins Nutrition 0.000 claims description 76
- 235000001014 amino acid Nutrition 0.000 claims description 61
- 210000004027 cell Anatomy 0.000 claims description 55
- 102000003960 Ligases Human genes 0.000 claims description 50
- 108090000364 Ligases Proteins 0.000 claims description 50
- 150000007523 nucleic acids Chemical group 0.000 claims description 50
- 108020004707 nucleic acids Proteins 0.000 claims description 48
- 102000039446 nucleic acids Human genes 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 46
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 35
- 239000013598 vector Substances 0.000 claims description 26
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 25
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 25
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 14
- 108091000100 Tyrosine Phenol-Lyase Proteins 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 235000004279 alanine Nutrition 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical group 0.000 claims description 6
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 5
- 210000002865 immune cell Anatomy 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 4
- 125000000732 arylene group Chemical group 0.000 claims description 4
- 125000005549 heteroarylene group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 claims description 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 3
- 125000005717 substituted cycloalkylene group Chemical group 0.000 claims description 3
- 102000014914 Carrier Proteins Human genes 0.000 claims description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 2
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 2
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 2
- 108091008324 binding proteins Proteins 0.000 claims description 2
- 125000001151 peptidyl group Chemical group 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 102000025171 antigen binding proteins Human genes 0.000 claims 1
- 108091000831 antigen binding proteins Proteins 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract description 42
- 235000019000 fluorine Nutrition 0.000 abstract description 32
- 230000009257 reactivity Effects 0.000 abstract description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 81
- 229940024606 amino acid Drugs 0.000 description 55
- 229910052731 fluorine Inorganic materials 0.000 description 33
- 229960004441 tyrosine Drugs 0.000 description 33
- 239000011737 fluorine Substances 0.000 description 29
- -1 n-octyl Chemical group 0.000 description 26
- 125000001424 substituent group Chemical group 0.000 description 25
- 238000004293 19F NMR spectroscopy Methods 0.000 description 23
- 238000005160 1H NMR spectroscopy Methods 0.000 description 21
- OUYCCCASQSFEME-QMMMGPOBSA-N L-Tyrosine Natural products OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 17
- 125000000217 alkyl group Chemical group 0.000 description 16
- 125000000753 cycloalkyl group Chemical group 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 125000003118 aryl group Chemical group 0.000 description 14
- 125000005842 heteroatom Chemical group 0.000 description 11
- 150000008553 L-tyrosines Chemical class 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- BDIBYQORZHGDIR-UHFFFAOYSA-N fluorosulfonyloxybenzene Chemical class FS(=O)(=O)OC1=CC=CC=C1 BDIBYQORZHGDIR-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 7
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- 238000004132 cross linking Methods 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000006142 Luria-Bertani Agar Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- WEJIXBMNLWITCR-QMMMGPOBSA-N (2s)-2-amino-3-(2-fluoro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1F WEJIXBMNLWITCR-QMMMGPOBSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 150000003668 tyrosines Chemical class 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- HFHFGHLXUCOHLN-UHFFFAOYSA-N 2-fluorophenol Chemical compound OC1=CC=CC=C1F HFHFGHLXUCOHLN-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000009482 thermal adhesion granulation Methods 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- XWNMQLVJIYFCFZ-YFKPBYRVSA-N (2s)-2-amino-3-(2,3-difluoro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(F)=C1F XWNMQLVJIYFCFZ-YFKPBYRVSA-N 0.000 description 1
- HEYMKHHKRTUJHU-ZETCQYMHSA-N (2s)-2-amino-3-(2,5-difluoro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(F)=C(O)C=C1F HEYMKHHKRTUJHU-ZETCQYMHSA-N 0.000 description 1
- KPKMCRFCNWVLDA-ZETCQYMHSA-N (2s)-2-amino-3-(3,5-difluoro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(F)=C(O)C(F)=C1 KPKMCRFCNWVLDA-ZETCQYMHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- CZXRUUCEAWTZOS-UHFFFAOYSA-N 1-fluoro-3-fluorosulfonyloxybenzene Chemical compound Fc1cccc(OS(F)(=O)=O)c1 CZXRUUCEAWTZOS-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- VIIAUOZUUGXERI-ZETCQYMHSA-N 3-fluoro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(F)=C1 VIIAUOZUUGXERI-ZETCQYMHSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241001521739 Colon Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical group C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Chemical group CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 101710132682 Lysozyme 1 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910003849 O-Si Inorganic materials 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910003872 O—Si Inorganic materials 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000005238 alkylenediamino group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000001314 canonical amino-acid group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Chemical group 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C305/00—Esters of sulfuric acids
- C07C305/26—Halogenosulfates, i.e. monoesters of halogenosulfuric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P9/00—Preparation of organic compounds containing a metal or atom other than H, N, C, O, S or halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
Definitions
- protein drugs represented by antibodies can specifically bind to large interaction surfaces, making it possible to disrupt protein-protein interaction.
- the intact IgG antibodies have remarkable pharmacokinetics, but can only bind to the surface of the tissue surface due to their large size.
- the corresponding fragment antibodies have better tissue permeability, but is limited by worse half-life. It may be that if the fragment antibodies covalently bind to the antigen, it is expected to avoid the limitations while remaining its intrinsic advantages.
- n is more than 0, and X is selected from the electron-withdrawing group.
- the present application provides a compound having the structure (II) of:
- n is more than 0, and X is selected from the electron-withdrawing group.
- n is more than 0, and X is selected from the electron-withdrawing group.
- the present application provides a compound having the structure (I-P) of:
- n is more than 0, and X is selected from the electron-withdrawing group.
- the present application provides a compound having the structure (II-A) of:
- n is more than 0, and X is selected from the electron-withdrawing group.
- the present application provides a compound having the structure (II-P) of:
- n is more than 0, and X is selected from the electron-withdrawing group.
- the present application provides a compound having the structure of:
- said X is selected from the electron-withdrawing group.
- said X is selected from the electron-withdrawing group.
- n is more than 0, and X is selected from the electron-withdrawing group.
- the present application provides a synthetase comprising a mutant at position 366 and/or position 367 as set forth in sequence of SEQ ID NO: 29.
- the present application provides a synthetase comprising a sequence of SEQ ID NO: 31 and/or 34.
- the present application provides a nucleic acid comprising a sequence encoding the synthetase of any of the present application.
- the present application provides a vector comprising the nucleic acid of any of the present application.
- the present application provides a combination comprising the synthetase of any of the present application and the compound of any of the present application.
- the present application provides a method of preparing the protein of any of the present application, wherein said method comprises providing the synthetase of any of the present application, the compound of any of the present application and/or the combination of any of the present application.
- the present application provides a composition comprising the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application and/or the cell of any of the present application, and optionally a pharmaceutically acceptable adjuvant.
- the present application provides a method for inhibiting binding of a PD-L1 protein to a PD-L1 ligand, wherein said method comprises providing the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application, the cell of any of the present application, the composition of any of the present application, and/or the kit of any of the present application.
- the present application provides a method for crosslinking PD-L1 protein, wherein said method comprises providing the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application, the cell of any of the present application, the composition of any of the present application, and/or the kit of any of the present application.
- the present application provides a method of preparing a compound having the structure (M) of:
- n is more than 0, and X is selected from the electron-withdrawing group; wherein said method comprises providing a ligase comprising sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 25, and SEQ ID NO: 27.
- the present application provides a ligase comprising sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 25, and SEQ ID NO: 27, for use in preparing a compound having the structure (M) of:
- n is more than 0, and X is selected from the electron-withdrawing group.
- FIG. 1 illustrates a general structure of electron-withdrawing fluorine substituted fluorosulfate with enhanced reactivity.
- FIG. 2 illustrates chemical structure of fluorine substituted phenyl sulfurofluoridate.
- FIGs. 3A-3D illustrate LC analysis of model reaction to determine the proximal reactivity of fluorine substituted phenyl sulfurofluoridate.
- FIG. 4 illustrates result of the proximal reactivity of fluorine substituted phenyl sulfurofluoridate.
- FIG. 5 illustrates specific activity of TPLs from different sources for 2-fluoro-L-tyrosine synthesis.
- FIG. 7 illustrates chemical structure of TPL catalyzed synthesis of fluorine substituted L-tyrosine.
- FIG. 8 illustrates chemical structure of fluorine substituted fluorosulfate L-tyrosine.
- FIGs. 9A-9D illustrate LC analysis of model reaction to determine the proximal reactivity of fluorosulfate L-tyrosine.
- FIG. 10 illustrates result of the proximal reactivity of fluorine substituted fluorosulfate L-tyrosine.
- FIGs. 11A-11C illustrate Sequencing result of the tRNA synthetase library.
- One dominant clone V366A for fluorosulfate-2, 6-difluoro-L-tyrosine was obtained from the randomly mutated library after four rounds of positive selection.
- A Before selection.
- B After three rounds of positive selection.
- C After additional one round of positive selection.
- FIG. 12 illustrates Amber suppression efficiency tested by a GFP reporter assay.
- GFP N194TAG is expressed in the presence of tRNA synthetase and corresponding PrUAAs.
- the fluorescent intensity in each group is measured by a plate reader and normalised by the strongest one.
- FIG. 13 illustrates Western blotting analysis of amber suppression efficiency.
- GFP N194TAG with a 6xHis tag at the C terminal is expressed in the presence of tRNA synthetase and corresponding PrUAAs.
- the fluorescent intensity in each group is measured by a plate reader and normalised by the strongest one.
- FIGs. 14A-14D illustrates result of successful incorporation of PrUAA into Nb-PD-L1 by ESI-MS.
- A For FSY, the measured MW is 16147 Da (calculated 16148 Da) .
- B For m-F FSY, the measured MW is 16166 Da (calculated 16147 Da) .
- C For o-F FSY, the measured MW is 16166 Da (calculated 16166 Da) .
- D For 2, 5-diF FSY, the measured MW is 16183 Da (calculated 16184 Da) .
- FIG. 15 illustrates comparison of the crosslinking efficiency of different GlueBodies with PD-L1. Purified proteins were incubated with PD-L1 at 37 °C for 1 h before SDS-PAGE and Coomassie staining.
- FIG. 16 illustrates quantification analysis of luciferase activities in T cells after coculturing with PD-L1+ aAPCs treated with the indicated protein drugs for 12 h.
- substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., -CH 2 O-is equivalent to -OCH 2 -.
- alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched carbon chain (or carbon) , or combination thereof, which may be fully saturated, mono-or polyunsaturated and can include mono-, di-and multivalent radicals.
- the alkyl may include a designated number of carbons (e.g., C 1 -C 10 means one to ten carbons) .
- Alkyl is an uncyclized chain.
- saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
- An unsaturated alkyl group is one having one or more double bonds or triple bonds.
- Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2- (butadienyl) , 2, 4-pentadienyl, 3- (1, 4-pentadienyl) , ethynyl, 1-and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
- An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (-O-) .
- An alkyl moiety may be an alkenyl moiety.
- An alkyl moiety may be an alkynyl moiety.
- An alkyl moiety may be fully saturated.
- An alkenyl may include more than one double bond and/or one or more triple bonds in addition to the one or more double bonds.
- An alkynyl may include more than one triple bond and/or one or more double bonds in addition to the one or more triple bonds.
- alkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, -CH 2 CH 2 CH 2 CH 2 -.
- an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein.
- a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
- alkenylene, ” by itself or as part of another substituent means, unless otherwise stated, a divalent radical derived from an alkene.
- heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S) , and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
- the heteroatom (s) e.g., N, S, Si, or P
- Heteroalkyl is an uncyclized chain.
- Examples include, but are not limited to: -CH 2 -CH 2 -O-CH 3 , -CH 2 -CH 2 -NH-CH 3 , -CH 2 -CH 2 -N (CH 3 ) -CH 3 , -CH 2 -S-CH 2 -CH 3 , -CH 2 -CH 2 , -S (O) -CH 3 , -CH 2 -CH 2 -S (O) 2 -CH 3 , -CH ⁇ CHO-CH 3 , -Si (CH 3 ) 3 , -CH 2 -CH ⁇ N-OCH 3 , -CH ⁇ CH-N (CH 3 ) -CH 3 , -O-CH 3 , -O-CH 2 -CH 3 , and -CN.
- heteroalkyl moiety may include 1, 2, 3, 4 or 5 heteroatom (e.g., O, N, S, Si, or P) .
- a heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P) .
- heteroalkenyl, ” by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one double bond.
- a heteroalkenyl may optionally include more than one double bond and/or one or more triple bonds in additional to the one or more double bonds.
- a heteroalkynyl may optionally include more than one triple bond and/or one or more double bonds in additional to the one or more triple bonds.
- heteroalkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH 2 -CH 2 -S-CH 2 -CH 2 -and -CH 2 -S-CH 2 -CH 2 -NH-CH 2 -.
- heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like) .
- heteroalkyl groups include those groups that are attached to the remainder of the molecule through a heteroatom, such as -C (O) R′, -C (O) NR′, -NR′R′′, -OR′, -SR′, and/or -SO 2 R′.
- heteroalkyl is recited, followed by recitations of specific heteroalkyl groups, such as -NR′R′′or the like, it will be understood that the terms heteroalkyl and -NR′R′′are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as -NR′R′′or the like.
- cycloalkyl and heterocycloalkyl by themselves or in combination with other terms, mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl, ” respectively. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
- heterocycloalkyl examples include, but are not limited to, 1- (1, 2, 5, 6-tetrahydropyridyl) , 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
- a “cycloalkylene” and a “heterocycloalkylene, ” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively.
- cycloalkyl means a monocyclic, bicyclic, or a multicyclic cycloalkyl ring system.
- monocyclic ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups can be saturated or unsaturated, but not aromatic.
- cycloalkyl groups are fully saturated. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.
- Bicyclic cycloalkyl ring systems are bridged monocyclic rings or fused bicyclic rings.
- bridged monocyclic rings contain a monocyclic cycloalkyl ring where two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms (i.e., a bridging group of the form (CH 2 ) w , where w is 1, 2, or 3) .
- a cycloalkyl is a cycloalkenyl.
- the term “cycloalkenyl” is used in accordance with its plain ordinary meaning.
- a cycloalkenyl is a monocyclic, bicyclic, or a multicyclic cycloalkenyl ring system.
- monocyclic cycloalkenyl ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups are unsaturated (i.e., containing at least one annular carbon carbon double bond) , but not aromatic.
- a heterocycloalkyl is a heterocyclyl.
- heterocyclyl as used herein, means a monocyclic, bicyclic, or multicyclic heterocycle.
- the heterocyclyl monocyclic heterocycle is a 3, 4, 5, 6 or 7 membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S where the ring is saturated or unsaturated, but not aromatic.
- halo or halogen, ” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
- acyl means, unless otherwise stated, -C (O) R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- aryl means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently.
- a fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring.
- heteroaryl refers to aryl groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom (s) are optionally quaternized.
- alkyl, ” “heteroalkyl, ” “cycloalkyl, ” “heterocycloalkyl, ” “aryl, ” and “heteroaryl” includes both substituted and unsubstituted forms of the indicated radical.
- Substituents for rings may be depicted as substituents on the ring rather than on a specific atom of a ring (commonly referred to as a floating substituent) .
- Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups.
- Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure.
- each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in aspects, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In aspects, at least one or all of these groups are substituted with at least one size-limited substituent group. In aspects, at least one or all of these groups are substituted with at least one lower substituent group.
- Optically active (R) -and (S) -, or (D) -and (L) -isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
- the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
- isomers refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.
- tautomer refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another.
- structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
- compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C-or 14 C-enriched carbon are within the scope of this disclosure.
- an analog or “analogue” is used in accordance with its plain ordinary meaning within Chemistry and Biology and refers to a chemical compound that is structurally similar to another compound (i.e., a so-called “reference” compound) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound. Accordingly, an analog is a compound that is similar or comparable in function and appearance but not in structure or origin to a reference compound.
- R-substituted where a moiety is substituted with an R substituent, the group may be referred to as “R-substituted. ” Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different.
- R group is present in the description of a chemical genus (such as Formula (I) )
- a Roman alphabetic symbol may be used to distinguish each appearance of that particular R group.
- each R 13 substituent may be distinguished as R 13A , R 13B , R 13C , R 13D , etc., wherein each of R 13A , R 13B , R 13C , R 13D , etc. is defined within the scope of the definition of R 13 and optionally differently.
- n is more than 0, and X is selected from the electron-withdrawing group.
- n is more than 0, and X is selected from the electron-withdrawing group.
- said compound having the structure of: may have better reactivity.
- the present application provides a compound having the structure of: wherein, said X is selected from the electron-withdrawing group.
- n is more than 0, and X is selected from the electron-withdrawing group.
- said protein comprises an unnatural amino acid having the structure of the compound of any of the present application.
- the present application provides a synthetase comprising an alanine at position 366 and/or position 367 as set forth in sequence of SEQ ID NO: 29.
- the amino acid of synthetase of the present application comprise an alanine instead of the original chFSYRS.
- the amino acid of synthetase of the present application comprise an alanine instead of the original amino acid of SEQ ID NO: 29.
- the present application provides a synthetase comprising a sequence of SEQ ID NO: 31 and/or 34.
- the present application provides a nucleic acid comprising a sequence of SEQ ID NO: 30 and/or 33.
- the present application provides a method of preparing the protein of any of the present application, wherein said method comprises providing the synthetase of any of the present application, the compound of any of the present application and/or the combination of any of the present application.
- the present application provides a cell comprising the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, and/or the combination of any of the present application.
- the present application provides a composition comprising the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application and/or the cell of any of the present application, and optionally a pharmaceutically acceptable adjuvant.
- the present application provides a kit comprising the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application, the cell of any of the present application, and/or the composition of any of the present application.
- the present application provides a method for crosslinking PD-L1 protein, wherein said method comprises providing the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application, the cell of any of the present application, the composition of any of the present application, and/or the kit of any of the present application.
- the present application provides a method for activating immune cell, wherein said method comprises providing the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application, the cell of any of the present application, the composition of any of the present application, and/or the kit of any of the present application.
- said immune cell comprises T cell.
- said method may be an in vitro method.
- the present application provides a method of preparing a compound having the structure (M) of:
- n is more than 0, and X is selected from the electron-withdrawing group; wherein said method comprises providing a ligase comprising sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 25, and SEQ ID NO: 27.
- the present application provides a ligase comprising sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 25, and SEQ ID NO: 27, for use in preparing a compound having the structure (M) of:
- n is more than 0, and X is selected from the electron-withdrawing group.
- said method comprises providing a ligase encoded by sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 20, SEQ ID NO: 24, and SEQ ID NO: 26.
- n is selected from the group consisting of: 1, 2, 3 and 4.
- each of said X is independently halogen.
- each of said X is independently F.
- said compound comprises the structure of:
- Standard abbreviations may be used, e.g., bp, base pair (s) ; kb, kilobase (s) ; pl, picoliter (s) ; s or sec, second (s) ; min, minute (s) ; h or hr, hour (s) ; aa, amino acid (s) ; nt, nucleotide (s) ; i.m., intramuscular (ly) ; i.p., intraperitoneal (ly) ; s.c., subcutaneous (ly) ; and the like.
- the present application provides an electron-withdrawing fluorine substituted fluorosulfate with enhanced reactivity.
- the present application provides chemical structure of fluorine substituted phenyl sulfurofluoridate.
- the model reaction was designed, in which the concentration of imidazole was 100-fold than sulfurofluridate to accelerate the reaction.
- 100 ⁇ L 10 mM fluorine substituted phenyl sulfurofluoridate solution in CH 3 CN was mixed with 900 ⁇ L 110 mM imidazole solution (pH 8.5) in a 1.5 mL EP tube.
- the tube was placed in a thermal shaker and the reaction was conducted at 30 °C at 1000 rpm for 4 h.
- the mixture was analyzed by UPLC and absorption at 260 nm from benzene group was monitored and the conversion rate was calculated with the formula: Area of product / (Area of product + Area of reactant) x 100%.
- TPL tyrosine phenol lyase
- the Amino acid sequences encoding TPLs were obtained from Uniprot (www. uniprot. org) database, patents (CN109897845A) and literatures (European Journal of Organic Chemistry 2020, 8, 1050-1054., Journal of Industrial Microbiology and Biotechnology 2019, 12, 1631-1641. ) .
- the corresponding DNA sequences were synthesized by GENEWIZ (Shanghai, China) with codon optimization against E. coli as host.
- the synthesized gene with a 6 ⁇ His-tag at N terminal was flanked with the endonuclease sites of Nco I and Not I, which was digested by the two corresponding restriction enzymes, respectively and inserted into pre-digested vector pET-28a (+) with the same restriction enzymes termed pET-28a (+) -XX TPL plasmid.
- Plasmids pET-28a (+) -XX TPL was transformed into BL21 (DE3) by heat shock method.
- the transformants were plated on an LB-Kanamycin agar plate and incubated overnight at 37 °C.
- a single colony was inoculated into 10 mL of LB medium containing 50 ⁇ g/mL kanamycin at 37 °C.
- 10 mL of overnight cell culture was diluted into 1 L fresh LB medium agitated vigorously at 37 °C.
- OD600 reached 0.4 ⁇ 0.6
- IPTG was added to the final concentration of 0.5 mM, then induced at 30 °C for 12h.
- the cells were then harvested by centrifugation at 6,000g for 20 min and stored at -80 °C before usage.
- the present application provides specific activity of TPLs from different sources for 2-fluoro-L-tyrosine synthesis.
- the present application provides chemical structure of TPL catalyzed synthesis of fluorine substituted L-tyrosine.
- the present application provides chemical structure of fluorine substituted fluorosulfate L-tyrosine.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed are a substituted fluorosulfate and use thereof, and fluorines substituted fluorosulfate and non-natural amino acid (covalent amino acid, PrUAA) with enhanced reactivity.
Description
Covalent drugs have been drawing attentions from both basic research and industry. Covalent drugs have two step combined mechanisms: First, the drug binds to the target via reversible non-covalent interaction; then, the drug would react with the electrophilic amino acid residue on the target through proximity mediated reaction, forming a covalent bond linked conjugate. Additional covalent bonds enable the drug molecules to not dissociate from the target, which extends the duration time of the drug molecule. Thus, covalent drugs would have a stronger and durable efficacy when compared to its non-covalent counterpart.
Due to the structure limitation of small molecular drugs, they often bind to the "pocket" of the protein, in the form of inhibitors. However, protein drugs represented by antibodies can specifically bind to large interaction surfaces, making it possible to disrupt protein-protein interaction. In the clinical practice, the intact IgG antibodies have remarkable pharmacokinetics, but can only bind to the surface of the tissue surface due to their large size. The corresponding fragment antibodies have better tissue permeability, but is limited by worse half-life. It may be that if the fragment antibodies covalently bind to the antigen, it is expected to avoid the limitations while remaining its intrinsic advantages.
With the help of genetic codon expansion technology, non-canonical amino acids carrying a new chemical functional group can be introduced into the target protein, which greatly expands the space of protein engineering. In principle, covalent protein drugs should specifically cross-link with target antigens, while avoiding reacting with the active compounds or other proteins in the living system. This property requires the residue of the introduced proximal reactive unnatural amino acid (covalent amino acid, PrUAA) must have moderate reactivity, which can stably present in a complex biological system and react with target after the antibody binding. Obviously, the warhead of the covalent amino acid is the key factor affecting the cross-linking efficiency of covalent protein drugs. However, there are few suitable functional groups meet the above requirements. Therefore, there is a great need for
developing biocompatible and high proximal reactive functional groups and related covalent amino acids, which would greatly facilitate the development of covalent protein drugs.
The present disclosure provides a substituted fluorosulfate and use thereof. And fluorines substituted fluorosulfate and related PrUAAs with enhanced reactivity are developed in the present application. Covalent protein drugs have been drawing extensive attention from both research and industry. while the site-specific incorporation of proximal-reactive unnatural amino acids (PrUAAs) into proteins through genetic code expansion strategy is one of the important methods to endow proteins with covalent binding capacity, lacking of proper unnatural amino acids greatly limit the development of covalent protein drugs. The fluorosulfate has good biocompatibility but relatively low proximal reactivity. Therefore, we chemoenzymatically generated fluorines substituted fluorosulfate and related PrUAAs with enhanced reactivity. On this basis, we further developed series of covalent single-domain antibodies targeting PD-L1 and confirmed their enhanced efficacy in restoring T cell activity, demonstrating the potentiality of covalent antibody as a new generation of biological drugs.
In one aspect, the present application provides a compound having the structure (I) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
In another aspect, the present application provides a compound having the structure (II) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
In another aspect, the present application provides a compound having the structure (I-A) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
In another aspect, the present application provides a compound having the structure (I-P) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
In another aspect, the present application provides a compound having the structure (II-A) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
In another aspect, the present application provides a compound having the structure (II-P) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
In another aspect, the present application provides a compound having the structure of:
wherein, said X is selected from the electron-withdrawing group.
In another aspect, the present application provides a compound having the structure of:
wherein, said X is selected from the electron-withdrawing group.
In another aspect, the present application provides a protein comprising the structure of the compound of any of the present applications.
In another aspect, the present application provides a protein comprising an unnatural amino acid having the structure (I) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
In another aspect, the present application provides a protein comprising an unnatural amino acid having the structure of:
In another aspect, the present application provides a nucleic acid comprising a sequence encoding the protein of any of the present application.
In another aspect, the present application provides a synthetase comprising a mutant at position 366 and/or position 367 as set forth in sequence of SEQ ID NO: 29.
In another aspect, the present application provides a synthetase comprising an alanine at position 366 and/or position 367 as set forth in sequence of SEQ ID NO: 29.
In another aspect, the present application provides a synthetase comprising a sequence of SEQ ID NO: 31 and/or 34.
In another aspect, the present application provides a nucleic acid comprising a sequence encoding the synthetase of any of the present application.
In another aspect, the present application provides a nucleic acid comprising a sequence of SEQ ID NO: 30 and/or 33.
In another aspect, the present application provides a vector comprising the nucleic acid of any of the present application.
In another aspect, the present application provides a combination comprising the synthetase of any of the present application and the compound of any of the present application.
In another aspect, the present application provides a method of preparing the protein of any of the present application, wherein said method comprises providing the synthetase of any of the present application, the compound of any of the present application and/or the combination of any of the present application.
In another aspect, the present application provides a cell comprising the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, and/or the combination of any of the present application.
In another aspect, the present application provides a composition comprising the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of
the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application and/or the cell of any of the present application, and optionally a pharmaceutically acceptable adjuvant.
In another aspect, the present application provides a kit comprising the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application, the cell of any of the present application, and/or the composition of any of the present application.
In another aspect, the present application provides a method for inhibiting binding of a PD-L1 protein to a PD-L1 ligand, wherein said method comprises providing the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application, the cell of any of the present application, the composition of any of the present application, and/or the kit of any of the present application. In another aspect, the present application provides a method for crosslinking PD-L1 protein, wherein said method comprises providing the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application, the cell of any of the present application, the composition of any of the present application, and/or the kit of any of the present application.
In another aspect, the present application provides a method for activating immune cell, wherein said method comprises providing the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the
vector of any of the present application, the combination of any of the present application, the cell of any of the present application, the composition of any of the present application, and/or the kit of any of the present application.
In another aspect, the present application provides a method of preparing a compound having the structure (M) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group; wherein said method comprises providing a ligase comprising sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 25, and SEQ ID NO: 27.
In another aspect, the present application provides a ligase comprising sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 25, and SEQ ID NO: 27, for use in preparing a compound having the structure (M) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.
INCORPORATION BY REFERENCES
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWING
The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are employed, and the accompanying drawings (also “figure” and “FIG. ” herein) , of which:
FIG. 1 illustrates a general structure of electron-withdrawing fluorine substituted fluorosulfate with enhanced reactivity.
FIG. 2 illustrates chemical structure of fluorine substituted phenyl sulfurofluoridate.
FIGs. 3A-3D illustrate LC analysis of model reaction to determine the proximal reactivity of fluorine substituted phenyl sulfurofluoridate.
FIG. 4 illustrates result of the proximal reactivity of fluorine substituted phenyl sulfurofluoridate.
FIG. 5 illustrates specific activity of TPLs from different sources for 2-fluoro-L-tyrosine synthesis.
FIG. 6 illustrates Cf TPL and Fn TPL demonstrate efficient synthesis of difluorine substituted L-tyrosine.
FIG. 7 illustrates chemical structure of TPL catalyzed synthesis of fluorine substituted L-tyrosine.
FIG. 8 illustrates chemical structure of fluorine substituted fluorosulfate L-tyrosine.
FIGs. 9A-9D illustrate LC analysis of model reaction to determine the proximal reactivity of fluorosulfate L-tyrosine.
FIG. 10 illustrates result of the proximal reactivity of fluorine substituted fluorosulfate L-tyrosine.
FIGs. 11A-11C illustrate Sequencing result of the tRNA synthetase library. One dominant clone V366A for fluorosulfate-2, 6-difluoro-L-tyrosine was obtained from the randomly mutated
library after four rounds of positive selection. (A) Before selection. (B) After three rounds of positive selection. (C) After additional one round of positive selection.
FIG. 12 illustrates Amber suppression efficiency tested by a GFP reporter assay. GFP N194TAG is expressed in the presence of tRNA synthetase and corresponding PrUAAs. The fluorescent intensity in each group is measured by a plate reader and normalised by the strongest one.
FIG. 13 illustrates Western blotting analysis of amber suppression efficiency. GFP N194TAG with a 6xHis tag at the C terminal is expressed in the presence of tRNA synthetase and corresponding PrUAAs. The fluorescent intensity in each group is measured by a plate reader and normalised by the strongest one.
FIGs. 14A-14D illustrates result of successful incorporation of PrUAA into Nb-PD-L1 by ESI-MS. (A) For FSY, the measured MW is 16147 Da (calculated 16148 Da) . (B) For m-F FSY, the measured MW is 16166 Da (calculated 16147 Da) . (C) For o-F FSY, the measured MW is 16166 Da (calculated 16166 Da) . (D) For 2, 5-diF FSY, the measured MW is 16183 Da (calculated 16184 Da) .
FIG. 15 illustrates comparison of the crosslinking efficiency of different GlueBodies with PD-L1. Purified proteins were incubated with PD-L1 at 37 ℃ for 1 h before SDS-PAGE and Coomassie staining.
FIG. 16 illustrates quantification analysis of luciferase activities in T cells after coculturing with PD-L1+ aAPCs treated with the indicated protein drugs for 12 h. The box and error bars represent the mean ± standard error of the mean (n=3) .
FIG. 17 illustrates fluorescence images of 293T cells transfected with pCMV EGFP Y40TAG and tRNA synthetase/tRNA. Cells were incubated with corresponding PrUAA for 24 h after transfection followed by fluorescence imaging. Scale bar= 150 μm.
While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing
from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.
Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., -CH2O-is equivalent to -OCH2-.
The term “alkyl, ” by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched carbon chain (or carbon) , or combination thereof, which may be fully saturated, mono-or polyunsaturated and can include mono-, di-and multivalent radicals. The alkyl may include a designated number of carbons (e.g., C1-C10 means one to ten carbons) . Alkyl is an uncyclized chain. Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2- (butadienyl) , 2, 4-pentadienyl, 3- (1, 4-pentadienyl) , ethynyl, 1-and 3-propynyl, 3-butynyl, and the higher homologs and isomers. An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (-O-) . An alkyl moiety may be an alkenyl moiety. An alkyl moiety may be an alkynyl moiety. An alkyl moiety may be fully saturated. An alkenyl may include more than one double bond and/or one or more triple bonds in addition to the one or more double bonds. An alkynyl may include more than one triple bond and/or one or more double bonds in addition to the one or more triple bonds.
The term “alkylene, ” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, -CH2CH2CH2CH2-. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein. A “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms. The term “alkenylene, ” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene.
The term “heteroalkyl, ” by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S) , and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heteroatom (s) (e.g., N, S, Si, or P) may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Heteroalkyl is an uncyclized chain. Examples include, but are not limited to: -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N (CH3) -CH3, -CH2-S-CH2-CH3, -CH2-CH2, -S (O) -CH3, -CH2-CH2-S (O) 2-CH3, -CH═CHO-CH3, -Si (CH3) 3, -CH2-CH═N-OCH3, -CH═CH-N (CH3) -CH3, -O-CH3, -O-CH2-CH3, and -CN. Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si (CH3) 3. A heteroalkyl moiety may include 1, 2, 3, 4 or 5 heteroatom (e.g., O, N, S, Si, or P) . A heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P) . The term “heteroalkenyl, ” by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one double bond. A heteroalkenyl may optionally include more than one double bond and/or one or more triple bonds in additional to the one or more double bonds. The term “heteroalkynyl, ” by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one triple bond. A heteroalkynyl may optionally include more than one triple bond and/or one or more double bonds in additional to the one or more triple bonds.
The term “heteroalkylene, ” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH2-CH2-S-CH2-CH2-and -CH2-S-CH2-CH2-NH-CH2-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like) . Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C (O) 2R′-represents both -C (O) 2R′-and -R′C (O) 2-. As described above, heteroalkyl groups, as used herein, include those groups that are attached to the remainder of the molecule through a heteroatom, such as -C (O) R′, -C (O) NR′, -NR′R″, -OR′, -SR′, and/or -SO2R′. Where “heteroalkyl” is
recited, followed by recitations of specific heteroalkyl groups, such as -NR′R″or the like, it will be understood that the terms heteroalkyl and -NR′R″are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as -NR′R″or the like.
The terms “cycloalkyl” and “heterocycloalkyl, ” by themselves or in combination with other terms, mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl, ” respectively. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1- (1, 2, 5, 6-tetrahydropyridyl) , 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. A “cycloalkylene” and a “heterocycloalkylene, ” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively.
In embodiments, the term “cycloalkyl” means a monocyclic, bicyclic, or a multicyclic cycloalkyl ring system. In aspects, monocyclic ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups can be saturated or unsaturated, but not aromatic. In aspects, cycloalkyl groups are fully saturated. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Bicyclic cycloalkyl ring systems are bridged monocyclic rings or fused bicyclic rings. In aspects, bridged monocyclic rings contain a monocyclic cycloalkyl ring where two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms (i.e., a bridging group of the form (CH2) w, where w is 1, 2, or 3) .
In embodiments, a cycloalkyl is a cycloalkenyl. The term “cycloalkenyl” is used in accordance with its plain ordinary meaning. In aspects, a cycloalkenyl is a monocyclic, bicyclic, or a multicyclic cycloalkenyl ring system. In aspects, monocyclic cycloalkenyl ring systems are cyclic hydrocarbon
groups containing from 3 to 8 carbon atoms, where such groups are unsaturated (i.e., containing at least one annular carbon carbon double bond) , but not aromatic.
In embodiments, a heterocycloalkyl is a heterocyclyl. The term “heterocyclyl” as used herein, means a monocyclic, bicyclic, or multicyclic heterocycle. The heterocyclyl monocyclic heterocycle is a 3, 4, 5, 6 or 7 membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S where the ring is saturated or unsaturated, but not aromatic.
The terms “halo” or “halogen, ” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
The term “acyl” means, unless otherwise stated, -C (O) R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
The term “aryl” means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently. A fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring. The term “heteroaryl” refers to aryl groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom (s) are optionally quaternized.
Each of the above terms (e.g., “alkyl, ” “heteroalkyl, ” “cycloalkyl, ” “heterocycloalkyl, ” “aryl, ” and “heteroaryl” ) includes both substituted and unsubstituted forms of the indicated radical.
Substituents for rings (e.g., cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene) may be depicted as substituents on the ring rather than on a specific atom of a ring (commonly referred to as a floating substituent) .
Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups. Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure.
In embodiments, each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in aspects, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In aspects, at least one or all of these groups are substituted with at least one size-limited substituent group. In aspects, at least one or all of these groups are substituted with at least one lower substituent group.
Certain compounds of the present disclosure possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (R) -or (S) -or, as (D) -or (L) -for amino acids, and individual isomers are encompassed within the scope of the present disclosure. The compounds of the present disclosure do not include those that are known in art to be too unstable to synthesize and/or isolate. The present disclosure is meant to include compounds in racemic and optically pure forms. Optically active (R) -and (S) -, or (D) -and (L) -isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
As used herein, the term “isomers” refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.
The term “tautomer, ” as used herein, refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another.
Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the disclosure.
Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13C-or 14C-enriched carbon are within the scope of this disclosure.
The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H) , iodine-125 (125I) , or carbon-14 (14C) . All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.
It should be noted that throughout the application that alternatives are written in Markush groups, for example, each amino acid position that contains more than one possible amino acid. It is specifically contemplated that each member of the Markush group should be considered separately, thereby comprising another embodiment, and the Markush group is not to be read as a single unit.
“Analog, ” or “analogue” is used in accordance with its plain ordinary meaning within Chemistry and Biology and refers to a chemical compound that is structurally similar to another compound (i.e., a so-called “reference” compound) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound. Accordingly, an analog is a compound that is similar or comparable in function and appearance but not in structure or origin to a reference compound.
The terms “a” or “an, ” as used in herein means one or more. In addition, the phrase “substituted with a [n] , ” as used herein, means the specified group may be substituted with one or more of any or all of the named substituents. For example, where a group, such as an alkyl or heteroaryl group, is “substituted with an unsubstituted C1-C20 alkyl, or unsubstituted 2 to 20 membered heteroalkyl, ” the group may contain one or more unsubstituted C1-C20 alkyls, and/or one or more unsubstituted 2 to 20 membered heteroalkyls.
Moreover, where a moiety is substituted with an R substituent, the group may be referred to as “R-substituted. ” Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different. Where a particular R group is present in the description of a chemical genus (such as Formula (I) ) , a Roman alphabetic symbol may be used to distinguish each appearance of that particular R group. For example, where multiple R13 substituents are present, each R13 substituent may be distinguished as R13A, R13B, R13C, R13D, etc., wherein each of R13A, R13B, R13C, R13D, etc. is defined within the scope of the definition of R13 and optionally differently.
Descriptions of compounds of the present disclosure are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions. For example, a heterocycloalkyl or heteroaryl is attached to the remainder of the molecule via a ring heteroatom in compliance with principles of chemical bonding known to those skilled in the art thereby avoiding inherently unstable compounds.
A person of ordinary skill in the art will understand when a variable (e.g., moiety or linker) of a compound or of a compound genus (e.g., a genus described herein) is described by a name or formula of a standalone compound with all valencies filled, the unfilled valence (s) of the variable will be dictated by the context in which the variable is used. For example, when a variable of a compound as described herein is connected (e.g., bonded) to the remainder of the compound through a single bond, that variable is understood to represent a monovalent form (i.e., capable of forming a single bond due to an unfilled valence) of a standalone compound (e.g., if the variable is named “methane” in an embodiment but the variable is known to be attached by a single bond to the remainder of the compound, a person of ordinary skill in the art would understand that the variable is actually a monovalent form of methane, i.e., methyl or -CH3) .
As described herein the complementarity of sequences may be partial, in which only some of the nucleic acids match according to base pairing, or complete, where all the nucleic acids match
according to base pairing. Thus, two sequences that are complementary to each other, may have a specified percentage of nucleotides that are the same (i.e., about 60%identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region) .
The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, -carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. The terms “non-naturally occurring amino acid” and “unnatural amino acid” refer to amino acid analogs, synthetic amino acids, and amino acid mimetics which are not found in nature.
The terms “polypeptide, ” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues, wherein the polymer may in embodiments be conjugated to a moiety that does not consist of amino acids. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
In one aspect, the present application provides a compound having the structure (I) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
In another aspect, the present application provides a compound having the structure (II) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
For example, an electron-withdrawing group (EWG) may draw electron away from a reaction center. When this center is an electron rich carbanion or an alkoxide anion, the presence of the electron-withdrawing substituent has a stabilizing effect. Examples of electron withdrawing groups may be halogens (e.g., F, Cl) .
For example, the compound may be a biomolecule. For example, the compound may be a protein with a structure of the above structure. For example, the compound may be a protein with an unnatural amino acid having a structure of the above structure. For example, the compound may have the above structure as an intermolecular linker. For example, the compound may have the above structure as an intramolecular linker.
For example, wherein said structure (I) and/or structure (II) is linked to a linkage group R1, said R1 is optionally substituted substitution. For example, the compound may be a protein with an unnatural amino acid having a structure of the above structure. For example, the R1 may be R chain of the amino acid. For example, said structure (I) and/or structure (II) may be linked to the R chain of the amino acid.
For example, said R1 is a bond or is selected from group consisting of: -S (O) 2-, -NR1A-, -O-, -S-, -C (O) -, -C (O) NR1A-, -NR1AC (O) -, -NR1AC (O) NR1B-, -C (O) O-, -OC (O) -, optionally substituted alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, and optionally substituted heteroarylene, each said R1A and R1B is independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
For example, wherein said linkage group R1 is linked to a linkage group R2, said R2 is optionally substituted substitution. For example, the compound may be a protein with an unnatural
amino acid having a structure of the above structure. For example, the R2 may be peptide bond of the amino acid.
For example, said R2 is a bond or is selected from group consisting of: optionally substituted peptidyl moiety, optionally substituted nucleic acid moiety, and optionally substituted carbohydrate moiety.
For example, wherein said structure (I) and/or structure (II) is linked to said R2 via optionally substituted tyrosine.
In another aspect, the present application provides a compound having the structure (I-A) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
In another aspect, the present application provides a compound having the structure (I-P) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
In another aspect, the present application provides a compound having the structure (II-A) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
In another aspect, the present application provides a compound having the structure (II-P) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
For example, wherein said n is selected from the group consisting of: 1, 2, 3 and 4. For example, wherein said n is 1. For example, wherein said n is 2. For example, wherein said n is 3. For example, wherein said n is 4.
For example, wherein said compound having the structure of:
For example, wherein said compound having the structure of:
For example, said structure may have better reactivity.
For example, wherein said compound having the structure of:
For example, wherein said compound having the structure of:
In another aspect, the present application provides a compound having the structure of:wherein, said X is selected from the electron-withdrawing group.
In another aspect, the present application provides a compound having the structure of:
wherein, said X is selected from the electron-withdrawing group.
For example, wherein each of said X is independently halogen.
For example, wherein each of said X is independently F.
For example, wherein said compound having the structure of:
For example, wherein said compound having the structure of:
For example, said structure may have better reactivity.
For example, wherein said compound having the structure of:
For example, wherein said compound having the structure of:
For example, wherein said compound having the structure of:
For example, wherein said compound having the structure of:
For example, wherein said compound having the structure of:
For example, wherein said compound having the structure of:
For example, wherein said compound having the structure of:
For example, wherein said compound having the structure of:
For example, wherein said compound having the structure of:
For example, wherein said compound having the structure of:
In another aspect, the present application provides a protein comprising the structure of the compound of any of the present applications.
In another aspect, the present application provides a protein comprising an unnatural amino acid having the structure (I) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
For example, wherein said protein comprises an unnatural amino acid having the structure of the compound of any of the present application.
In another aspect, the present application provides a protein comprising an unnatural amino acid having the structure of:
For example, wherein said protein comprises said unnatural amino acid at position 108 as set forth in sequence of PD-L1 binding protein or the fragment thereof.
For example, wherein said protein comprises said unnatural amino acid at position 108 as set forth in sequence of anti-PD-L1 nanobody or the fragment thereof.
For example, wherein said protein comprises said unnatural amino acid at position 108 as set forth in sequence of SEQ ID NO: 1. For example, wherein said protein may further comprise p62, LC3, nucleotide 8-nitrocyclic guanosine monophosphate (8-nitro-cGMP) , mannose-6-phosphate, N-acetylgalactosamine (GalNAc) , cell-penetrating peptide and/or lysosome-sorting sequence.
In another aspect, the present application provides a nucleic acid comprising a sequence encoding the protein of any of the present application.
In another aspect, the present application provides a synthetase comprising a mutant at position 366 and/or position 367 as set forth in sequence of SEQ ID NO: 29.
In another aspect, the present application provides a synthetase comprising an alanine at position 366 and/or position 367 as set forth in sequence of SEQ ID NO: 29. For example, the amino acid of synthetase of the present application comprise an alanine instead of the original chFSYRS. For example, the amino acid of synthetase of the present application comprise an alanine instead of the original amino acid of SEQ ID NO: 29.
In another aspect, the present application provides a synthetase comprising a sequence of SEQ ID NO: 31 and/or 34.
In another aspect, the present application provides a nucleic acid comprising a sequence encoding the synthetase of any of the present application.
In another aspect, the present application provides a nucleic acid comprising a sequence of SEQ ID NO: 30 and/or 33.
In another aspect, the present application provides a vector comprising the nucleic acid of any of the present application.
In another aspect, the present application provides a combination comprising the synthetase of any of the present application and the compound of any of the present application.
In another aspect, the present application provides a method of preparing the protein of any of the present application, wherein said method comprises providing the synthetase of any of the present application, the compound of any of the present application and/or the combination of any of the present application.
In another aspect, the present application provides a cell comprising the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the
present application, the vector of any of the present application, and/or the combination of any of the present application.
In another aspect, the present application provides a composition comprising the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application and/or the cell of any of the present application, and optionally a pharmaceutically acceptable adjuvant.
In another aspect, the present application provides a kit comprising the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application, the cell of any of the present application, and/or the composition of any of the present application.
In another aspect, the present application provides a method for inhibiting binding of a PD-L1 protein to a PD-L1 ligand, wherein said method comprises providing the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application, the cell of any of the present application, the composition of any of the present application, and/or the kit of any of the present application. In another aspect, the present application provides a method for crosslinking PD-L1 protein, wherein said method comprises providing the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application, the cell of any of the present application, the composition of any of the present application, and/or the kit of any of the present application.
In another aspect, the present application provides a method for activating immune cell, wherein said method comprises providing the compound of any of the present application, the protein of any of the present application, the nucleic acid of any of the present application, the synthetase of any of the present application, the nucleic acid of any of the present application, the vector of any of the present application, the combination of any of the present application, the cell of any of the present application, the composition of any of the present application, and/or the kit of any of the present application.
For example, wherein said immune cell comprises T cell.
For example, wherein said activating is tested via luciferase assay.
For example, wherein said method may be an in vitro method.
In another aspect, the present application provides a method of preparing a compound having the structure (M) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group; wherein said method comprises providing a ligase comprising sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 25, and SEQ ID NO: 27.
In another aspect, the present application provides a ligase comprising sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 25, and SEQ ID NO: 27, for use in preparing a compound having the structure (M) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group.
For example, wherein said method comprises providing a ligase encoded by sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 20, SEQ ID NO: 24, and SEQ ID NO: 26.
For example, wherein said n is selected from the group consisting of: 1, 2, 3 and 4.
For example, wherein said compound comprises the structure of:
For example, wherein each of said X is independently halogen.
For example, wherein each of said X is independently F. For example, wherein said compound comprises the structure of:
The following examples are set forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended
to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc. ) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric. Standard abbreviations may be used, e.g., bp, base pair (s) ; kb, kilobase (s) ; pl, picoliter (s) ; s or sec, second (s) ; min, minute (s) ; h or hr, hour (s) ; aa, amino acid (s) ; nt, nucleotide (s) ; i.m., intramuscular (ly) ; i.p., intraperitoneal (ly) ; s.c., subcutaneous (ly) ; and the like.
Example 1
Development of fluoro substituted fluorosulfate with enhanced proximal reactivity
5.5 g fluorine substituted phenol was dissolved in 50 mL DCM and 10 mL Et3N (1.5 eq) . The mixture was stirred at room temperature for 10 min. Then, the atmosphere above the solution was removed with gentle vacuum, and SO2F2 gas was introduced by a needle from a balloon filled with the gas. The reaction mixture was vigorously stirred at room temperature for 6-72 hours, monitoring by TLC.
Phenyl sulfurofluoridate
1H NMR (400 MHz, DMSO) δ 7.63 –7.55 (m, 4H) , 7.55 –7.47 (m, 1H) . 13C NMR (101 MHz, DMSO) δ 150.22 (s) , 131.33 (s) , 129.70 (s) , 121.48 (s) . 19F NMR (377 MHz, DMSO) δ 38.24. MS: 175.0 [C6H4FO3S] -.
As shown in Fig. 1, the present application provides an electron-withdrawing fluorine substituted fluorosulfate with enhanced reactivity.
As shown in Fig. 2, the present application provides chemical structure of fluorine substituted phenyl sulfurofluoridate.
2-fluorophenyl sulfurofluoridate
1H NMR (400 MHz, DMSO) δ 7.70 –7.57 (m, 2H) , 7.43 (d, 2H) . 13C NMR (101 MHz, DMSO) δ 163.88, 161.41, 150.13, 132.65, 118.15 –116.96, 116.89, 110.22, 110.02 –108.68.19F NMR (377 MHz, DMSO) δ 38.79. MS: 193.0 [C6H3F2O3S] -.
3-fluorophenyl sulfurofluoridate
1H NMR (400 MHz, DMSO) δ 7.79 (t, 1H) , 7.64 –7.52 (m, 2H) , 7.44 –7.35 (m, 1H) . 13C NMR (101 MHz, DMSO) δ 154.39, 151.89, 136.83, 131.65, 126.60, 124.15, 118.51.19F NMR (377 MHz, DMSO) δ 39.41, -129.92. MS: 193.0 [C6H3F2O3S] -.
2,6-difluorophenyl sulfurofluoridate
1H NMR (400 MHz, DMSO) δ 7.64 (dt, 1H) , 7.49 (t, 2H) . 13C NMR (101 MHz, DMSO) δ 155.53, 153.00, 131.68, 125.76, 114.19.19F NMR (377 MHz, DMSO) δ 41.12, -126.70. MS: 211.0 [C6H2F3O3S] -.
2,5-difluorophenyl sulfurofluoridate
1H NMR (400 MHz, DMSO) δ 7.92 (ddd, 1H) , 7.68 (td, 1H) , 7.47 (ddt, 1H) . 13C NMR (101 MHz, DMSO) δ 159.24, 156.79, 151.27, 148.81, 136.47, 119.44, 118.36, 55.24.19F NMR (377 MHz, DMSO) δ 40.29, -113.99, -134.31. MS: 211.0 [C6H2F3O3S] -.
2,3-difluorophenyl sulfurofluoridate
1H NMR (400 MHz, DMSO) δ 7.73 –7.59 (m, 2H) , 7.44 (tdd, 1H) . 13C NMR (101 MHz, DMSO) δ 152.02, 149.53, 143.76, 141.31, 126.01, 119.67, 119.08, 55.25.19F NMR (377 MHz, DMSO) δ 39.90, -134.30, -152.73. MS: 211.2 [C6H2F3O3S] -.
3,5-difluorophenyl sulfurofluoridate
1H NMR (400 MHz, DMSO) δ 7.65 –7.55 (m, 2H) , 7.50 (tt, 1H) . 13C NMR (101 MHz, DMSO) δ 164.26, 150.17, 131.27, 107.20, 107.00, 105.97.19F NMR (377 MHz, DMSO) δ 39.50, -106.03. MS: 211.1 [C6H2F3O3S] -.
2, 3, 6-trifluorophenyl sulfurofluoridate
1H NMR (400 MHz, DMSO) δ 7.77 (tdd, 1H) , 7.57 (tdd, 1H) . 13C NMR (101 MHz, DMSO) δ151.73, 149.24, 148.40, 145.95, 144.63, 142.08, 126.53, 118.81, 113.25.
19F NMR (377 MHz, DMSO) δ 41.61, -130.78, -138.40, -147.59. MS: 229.1 [C6H1F4O3S] -.
LC analysis of the model reaction to determine the proximal reactivity of phenyl sulfurofluoridate derivatives
To test the proximal reactivity of fluorine substituted phenyl sulfurofluoridate toward nucleophilic group, the model reaction was designed, in which the concentration of imidazole was 100-fold than sulfurofluridate to accelerate the reaction. In detail: 100 μL 10 mM fluorine substituted phenyl sulfurofluoridate solution in CH3CN was mixed with 900 μL 110 mM imidazole solution (pH 8.5) in a 1.5 mL EP tube. The tube was placed in a thermal shaker and the reaction was conducted at 30 ℃ at 1000 rpm for 4 h. The mixture was analyzed by UPLC and absorption at 260 nm from benzene group was monitored and the conversion rate was calculated with the formula: Area of product / (Area of product + Area of reactant) x 100%.
As summarized in the (Figs. 3A-3D and Fig. 4) , both position and amounts of electro withdrawing fluorine atom have influence on the reactivity of sulfurofluridate. Especially, single fluorine substitution only slightly accelerates the reaction, while difluoro significantly accelerates the reaction.
Example 2
Chemoenzymatic synthesis of fluoro substituted fluorosulfate -L-tyrosine
Construction of plasmids encoding tyrosine phenol lyase (TPL) mutants
The Amino acid sequences encoding TPLs were obtained from Uniprot (www. uniprot. org) database, patents (CN109897845A) and literatures (European Journal of Organic Chemistry 2020, 8, 1050-1054., Journal of Industrial Microbiology and Biotechnology 2019, 12, 1631-1641. ) . The corresponding DNA sequences were synthesized by GENEWIZ (Shanghai, China) with codon optimization against E. coli as host. The synthesized gene with a 6 × His-tag at N terminal was flanked with the endonuclease sites of Nco I and Not I, which was digested by the two corresponding restriction enzymes, respectively and inserted into pre-digested vector pET-28a (+) with the same restriction enzymes termed pET-28a (+) -XX TPL plasmid.
Preparation of E. coli cells overexpressing TPLs
Plasmids pET-28a (+) -XX TPL was transformed into BL21 (DE3) by heat shock method. The transformants were plated on an LB-Kanamycin agar plate and incubated overnight at 37 ℃. A single colony was inoculated into 10 mL of LB medium containing 50 μg/mL kanamycin at 37 ℃. On the following day, 10 mL of overnight cell culture was diluted into 1 L fresh LB medium agitated vigorously at 37 ℃. When OD600 reached 0.4~0.6, IPTG was added to the final concentration of 0.5 mM, then induced at 30 ℃ for 12h. The cells were then harvested by centrifugation at 6,000g for 20 min and stored at -80 ℃ before usage.
General procedure of TPL catalyzed synthesis of fluorine substituted tyrosine by fed-batch method
Biosynthesis of fluorine substituted tyrosine was performed in 100 mL reaction mixture containing 50 mM sodium pyruvate, 50 mM ammonium chloride, 10 mM fluorophenol, 1.0 mM PLP, 0.1g/L TritonX-100, 2.0 g/L EDTA sodium and 15.0 g/L recombinant E. coli cells at pH 8.5 adjusted by ammonia. The reaction was carried out at 30 ℃ with shaking at 170 rpm for 24 h. During the reaction process, sodium pyruvate, fluorophenol and ammonium chloride were fed every 4 hours with a concentration of 5.0 g/L, 2.0 g/L and 3.5 g/L, respectively. The reaction can be monitored with 19F NMR.
After the synthesis reaction was completed, the pH was adjusted to 1-2 with 6 mol/L HCl solution and stirred vigorously for 1h, followed by filtration and remove the precipitation. The filtrate was then collected and gradually titrated up to pH7.0 with ammonia water (25-28 %) . Removing excess water under reduced pressure until there are about 100 mL residue. Thereafter, the L-tyrosine derivatives that evolved during the ammonia titration were recovered by filtration, washed twice with ice-cold water, and dried at 60 ℃ after being washed once more with ethanol.
As shown in Fig. 5, the present application provides specific activity of TPLs from different sources for 2-fluoro-L-tyrosine synthesis.
As shown in Fig. 6, the present application shows that Cf TPL and Fn TPL demonstrate efficient synthesis of difluorine substituted L-tyrosine.
As shown in Fig. 7, the present application provides chemical structure of TPL catalyzed synthesis of fluorine substituted L-tyrosine.
3-fluoro-L-tyrosine
1H NMR (400 MHz, D2O) δ 6.59 (d, 1H) , 6.54 –6.45 (m, 2H) , 3.89 –3.81 (m, 1H) , 2.78 (dd, 5.6 Hz, 1H) , 2.67 (dd, 1H) ; 19F NMR (377 MHz, D2O) δ -136.80 (dt, 7.7 Hz) ; MS: 198.3 [C9H9FNO3] -.
2-fluoro-L-tyrosine
1H NMR (400 MHz, D2O) δ 6.71 (dd, 1H) , 6.25 –6.19 (m, 2H) , 3.87 (t, 1H) , 2.85 (dd, 1H) , 2.71 (dd, 1H) ; 13C NMR (101 MHz, D2O) δ 170.79, 162.65, 160.23, 156.69, 132.15, 112.00 –111.29, 103.10, 102.85, 52.95, 28.58; 19F NMR (377 MHz, D2O) δ -115.85 –-116.00; MS: 198.2 [C9H9FNO3] -.
3,5-difluoro-L-tyrosine
19F NMR (377 MHz, D2O) δ -132.86 –-133.09 (m) ; MS: 216.3 [C9H8F2NO3] -.
2,5-difluoro-L-tyrosine
1H NMR (400 MHz, D2O) δ 6.72 (dd, 1H) , 6.43 (dd, 1H) , 3.97 (t, 1H) , 2.93 (dd, 1H) , 2.79 (dd, 1H) ; 19F NMR (377 MHz, D2O) δ -121.24 –-121.43, -142.09; MS: 218.1 [C9H10F2NO3] + .
2,3-difluoro-L-tyrosine
1H NMR (400 MHz, D2O) δ 6.46 (td, 1H) , 6.30 (t, 1H) , 3.85 (t, 1H) , 2.86 (dd, 1H) , 2.72 (dd, 1H) ; 19F NMR (377 MHz, D2O) δ -141.33, -161.29 –-161.54; MS: 216.3 [C9H8F2NO3] -.
2,6-difluoro-L-tyrosine
1H NMR (400 MHz, D2O) δ 6.24 –6.14 (m, 2H) , 3.94 (t, 1H) , 2.93 (dd, 1H) , 2.86 (dd, 1H) ; 19F NMR (377 MHz, D2O) δ -114.41 (d, J = 9.4 Hz) ; MS: 216.2 [C9H8F2NO3] -.
General synthesis procedure of fluorine substituted fluorosulfate-L-tyrosine from fluorine substituted L-tyrosine
5 g fluorine substituted L-tyrosine was dissolved in 50 mL 1M NaOH and 50 mL dioxane, followed by the dropwise addition of 10 mL (Boc) 2O (1 eq) for 2 h under stirring at room temperature. The mixture was further stirred for 1 h. Then, the solvent was removed under reduced pressure and the residue was dissolved in100 mL DCM, washed with 0.1 N HCl (2 × 75 mL) , saturated NaCl solution (2 × 75 mL) step by step. The aqueous layer was collected and solvent removal for following reaction without further purification.
To a 2 L two-neck round-bottom flask containing a magnetic stir bar was added 5 mmol Boc protected fluorine substituted L-tyrosine, 200 mL of CH2Cl2 and 800 mL of a saturated Borax solution. The mixture was stirred vigorously for 20 minutes. The reaction system was vacuumed until the
biphasic solution started to degas and refilled with SO2F2 for three times. The reaction mixture was stirred vigorously at room temperature overnight. CH2Cl2 was carefully removed using a rotary evaporator under reduced pressure. Then 1 M aqueous HCl (210 mL) was slowly added to the reaction mixture while stirring and white solid precipitated. The mixture was filtered and the solid was washed with ice cold water (3 × 75 mL) . The white solid was dried under vacuum overnight affording Boc protected fluorine substituted fluorosulfate-L-tyrosine, which was directly used in the next step without further purification. 5 mmol Boc protected fluorine substituted fluorosulfate-L-tyrosine was treated with 4 M HCl in dioxane (11 mL) and the reaction mixture was stirred for 4 h at room temperature, after which 50 mL ether was added to the mixture if there is no white solid precipitated. The solid was filtered and washed by cool ether (2 × 10 mL) , affording the targeted fluorine substituted L-tyrosine HCl salt. The product was analyzed with LC-MS and further purified by reverse phase preparative HPLC.
As shown in Fig. 8, the present application provides chemical structure of fluorine substituted fluorosulfate L-tyrosine.
Fluorosulfate-L-tyrosine
1H NMR (400 MHz, D2O) : δ (ppm) 3.23-3.41 (m, 2H) , 4.32-4.34 (m, 1H) , 7.45-7.53 (m, 4H) ; 13C NMR (400 MHz, D2O) : δ (ppm) 38.9, 57.2, 125.0, 135.3, 139.5, 153.5, 173.3; 19F NMR (400 MHz, D2O) : δ (ppm) 38.9, 57.2; MS: 264.0 [M+H] +.
Fluorosulfate-L-tyrosine
1H NMR (400 MHz, D2O) δ 7.38 (s, 4H) , 4.28 (dd, 1H) , 3.34 –3.24 (m, 1H) , 3.19 (dd, 1H) ; 13C NMR (101 MHz, D2O) δ 171.04, 149.44, 135.18, 131.51, 121.59, 66.53, 53.82, 34.87; 19F NMR (377 MHz, D2O) δ 37.49; MS: 262.2 [C9H9FNO5S] -.
Fluorosulfate-3-fluoro-L-tyrosine
1H NMR (500 MHz, D2O) : δ (ppm) 3.21-3.25 (m, 1H) , 3.32-3.36 (m, 1H) , 4.21-4.24 (t, 1H) , 7.22-7.58 (m, 3H) ; 13C NMR (500 MHz, D2O) : δ (ppm) 35.24, 54.28, 118.79, 123.79, 126.55, 136.30, 137.86, 153.14, 171.66; 19F NMR (500 MHz, D2O) : δ (ppm) -128.22, 38.82; MS: 282.0 [C9H10F2NO5S] +, 305.0 [C9H9F2NO5SNa] + .
Fluorosulfate-2-fluoro-L-tyrosine
1H NMR (500 MHz, D2O) : δ (ppm) 3.19-3.23 (m, 1H) , 3.33-3.37 (m, 1H) , 4.18-4.20 (t, 1H) , 7.26-7.46 (m, 3H) ; 13C NMR (500 MHz, D2O) : δ (ppm) 29.24, 53.34, 109.67, 117.50, 122.79, 133.19, 149.32, 161.54, 171.48; 19F NMR (500 MHz, D2O) : δ (ppm) -112.16, 37.85; MS: 282.0 [C9H10F2NO5S] +, 305.0 [C9H9F2NO5SNa] + .
Fluorosulfate-2, 3-difluoro-L-tyrosine
1H NMR (400 MHz, D2O) δ 7.35 (t, J = 7.7 Hz, 1H) , 7.25 –7.18 (m, 1H) , 4.31 –4.21 (m, 1H) , 3.38 (dd, J = 14.7, 6.4 Hz, 1H) , 3.25 (dd, J = 14.7, 7.1 Hz, 1H) ; 13C NMR (101 MHz, D2O) ) δ 170.81, 151.13, 148.65, 144.03, 141.49, 137.09, 126.26, 124.79, 118.48, 66.53, 52.77, 29.16; 19F NMR (377 MHz, D2O) δ 39.15, -136.33, -150.44; MS: 298.1 [C9H7F3NO5S] -, 597.2 [C18H15F6N2O10S2] -.
Fluorosulfate-2, 5-difluoro-L-tyrosine
1H NMR (400 MHz, D2O) δ 7.02 (dd, J = 8.8, 6.4 Hz, 1H) , 6.94 (dd, J = 10.1, 6.6 Hz, 1H) , 3.89 (t, J = 6.8 Hz, 1H) , 2.92 (dd, J = 14.7, 6.4 Hz, 1H) , 2.80 (dd, J = 14.7, 7.1 Hz, 1H) ; 13C NMR (151 MHz, D2O) δ 170.16, 150.23, 148.58, 135.64, 123.73, 119.80, 111.21, 52.53, 28.77; 19F NMR (377 MHz, D2O) δ 39.04, -117.77, -133.37;
MS: 298.2 [C9H7F3NO5S] -, 597.4 [C18H15F6N2O10S2] -.
Fluorosulfate-3, 5-difluoro-L-tyrosine
1H NMR (500 MHz, D2O) : δ (ppm) 3.17-3.20 (m, 1H) , 3.28-3.32 (m, 1H) , 4.20-4.22 (t, 1H) , 7.14-7.16 (d, 3H) ; 13C NMR (500 MHz, D2O) : δ (ppm) 35.31, 53.87, 114.22, 125.22, 138.00, 153.28, 171.25; 19F NMR (500 MHz, D2O) : δ (ppm) -124.96, 40.65; MS: 300.0 [C9H9F3NO5S] +, 323.0 [C9H8F3NO5S Na] + .
Fluorosulfate-2, 6-difluoro-L-tyrosine
1H NMR (400 MHz, DMSO) δ 7.68 (t, 2H) , 4.03 –3.92 (m, 1H) , 3.27 (dd, 1H) , 3.18 (dd, 1H) . 13C NMR (101 MHz, DMSO) δ 170.05, 162.85, 160.37, 148.77, 113.91, 106.88, 66.81, 56.45, 51.44 , 23.75, 19.00.19F NMR (377 MHz, DMSO) δ (ppm) 40.28, -109.06.
MS: 299.8 [C9H9F3NO5S] +.
LC analysis of the model reaction to determine the proximal reactivity of Fluorosulfate-L-tyrosine derivatives
Similar reaction was done to test the proximal reactivity of fluorine substituted L-tyrosine toward nucleophilic group: 100 μL 10 mM fluorine substituted L-tyrosine solution was mixed with 900 μL 110 mM imidazole solution (pH 8.5) in a 1.5 mL EP tube. The tube was placed in a thermal shaker and the reaction was conducted at 30 ℃ at 1000 rpm for 4 h. The mixture was analyzed by UPLC and absorption at 260 nm was monitored. The conversion rate was calculated with formula: Area of product/ (Area of product + Area of reactant) x 100%.
The result was summarized in the (Figs. 9A-9D and 10) , both position and amounts of electro withdrawing fluorine atom have influence on the reactivity of sulfurofluridate.
Example 3
Aminoacyl-tRNA Synthetase Selection against fluorosulfate-3, 5-difluoro-L-tyrosine
Construction of the pBK-chFSYRS S4 mutant library plasmids
pBK chFSYRS plasmid was generated by introducing the chFSYRS encoding gene from pSup chFSYRS into pBK vector via ligation independent cloning. Briefly, the chFSYRS gene was amplified with following primers, purified, and ligated into pBK vectors with Exnase II (Vazyme, Cat: C112-01) .
Considering the crystal structure of OMEY-MmPylRS synthetase, four residues are proximal to the backbone of tyrosine derivate, which may have interaction with newly introduced fluoro atoms. Therefore, the pBK-chFSYRS S4 mutant library (S364NNK, V366NNK, G384NNK, G386NNK) of chimera Mm/MbPylRS was constructed using whole plasmid amplification of the iterative saturation mutagenesis (ISM) approach, which introduce mutations during PCR by using synthetic DNA oligonucleotides containing one or more degenerate codons at the target residue. Firstly, primer S364-V366-NNK Forward and primer S364-V366-NNK Reverse containing degenerate codons (NNK) were used to amplify the pBK-chFSYRS plasmid. Then, the resultant library was treated with DpnI to eliminate the parental methylated DNA strands and transformed into DH10B cells. The cells were collected and extracted the plasmids with miniprep Kit to get the pBK-chFSYRS S2 mutant library. The above process was repeated with primer G384-G386-NNK Forward and primer G384-G386-NNK Reverse containing degenerate codons (NNK) using pBK-chFSYRS S2 mutant library as the template, resulting the final The pBK-chFSYRS S4 mutant library with 107 colones.
Selections of active chimeric FSYRS variants for UAAs were carried out with three rounds of positive selection and subsequently negative selection. chPheRS libraries in pBK vectors were firstly electroporated into DH10B competent cells harbouring the negative selection plasmid pPOS-CAT112TAGchPheT-GFP190TAG that contains CAT and GFP dual reporter genes with an amber codon (112TAG for CAT, 190TAG for GFP) , respectively. DH10B cells (100 μL) harboring the pPOS selection reporter was further transformed with 100 ng of pBK-chFSYRS S4 mutant library via electroporation. The electroporated cells were immediately recovered with 1 mL of pre-warmed SOC media and agitated vigorously at 37 ℃ for 1 h, followed by addition of fluorosulfate-3, 5-difluoro-L-tyrosine to the final concentration of 1 mM and agitated vigorously at 37 ℃ for another 1 h. The recovered cells were directly plated on a LB-agar selection plate supplemented with 1 mM fluorosulfate-3, 5-difluoro-L-tyrosine, 12.5 μg mL-1 of 50 μg/ml kanamycin (Kan) , 100 μg/mL of ampicillin (Amp) and 34 μg/mL of chloramphenicol (Cm) . The selection plate was incubated at 37 ℃for 48 h and then stored at room temperature. 57 clones present fluorosulfate-3, 5-difluoro-L-tyrosine -dependent growth were considered as hits and further characterized by Sanger-sequencing. During the positive selection, the pBK-chFSYRS S4 mutant library was parallelly electroporated into DH10B competent cells harboring the negative selection plasmid pNEG-Barnase-Q3TAG-D45TAG-chPheT. The transformed cells were recovered for 1 h at 37 ℃ then plated on LB agar containing 50 μg/mL kan, 100 μg/mL Amp and 34 μg/ml Cm and plated on a LB-agar selection plate. After 24 h of incubation at 37 ℃, there is no clone was found on the plate, which suggest that the synthetases are orthogonal to natural amino acids. Finally, a smaller synthetase library was generated based on the sequencing result and one more round of positive selection was conducted.
A unique amino acid sequence (S364S, V366A, G384G, G386G) was found in the sequencing result. Although the four sites were randomly mutated, three of them were enriched as the original residues, which suggest that they are highly conserved. pSup chFSYRS V366A plasmid was generated by site specifically introducing the Alanine mutation into chFSYRS using the following primers:
pSup chFSYRS V366A (Figs. 11A-11C) was subjected to further characterization to determine the fidelity and processivity of other fluoro substituted unnatural amino acids.
Assessment of amber suppression efficiency in E. coli
The plasmid pBAD GFP 149TAG bearing the GFP-149TAG with a 6xHis tag and the plasmid pSup chFSYRS V366A or pSup chFSYRS V366A carrying the corresponding chimeric synthetase were co-transformed into chemically competent DH10B cells, respectively. The transformed cells were recovered in SOC medium for 1 h with shaking at 37 ℃ and plated on LB agar containing 34 μg/ml chloramphenicol and 100 μg/ml ampicillin for 12 h at 37 ℃. A single colony was picked and grown in 2 ml of LB medium containing required antibiotics at 37 ℃ until OD600 reaching 0.4~0.6 and 1 mM of corresponding unnatural amino acids was added, then incubated at 30 ℃ for 30 min. The cell culture was induced with 0.2%arabinose and incubated at 30 ℃ for 10 h. After induction, 1 ml of cell cultures were collected by centrifuging, and then lyzed by 150 μl BugBuster Protein Extraction Reagent (Millipore) for 10 min at 37 ℃. The supernatant of the lysate (100 μl) was transferred to a 96-well cell culture plate (Costar) . And GFP signals of the supernatant were recorded by TECAN SPARK microplate reader with a background subtraction and normalized by the bacterial density (OD600) that was measured by TECAN SPARK microplate reader as well.
At the same time, 1 ml of cell cultures were collected by centrifuging and resuspended with 100 μL 1xloading buffer, heated at 95 ℃ for 30 min. 10 μL of samples were loaded in 4-20%or 8-16%sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) for electrophoresis and transferred to a 0.22 μm polyvinylidene fluoride (PVDF) membrane (Millipore) . After protein transfer, the membrane was blocked with 5%bovine serum albumin in TBST buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 0.1%Tween-20) for 1 h at room temperature with gentle shaking. The membrane was incubated with primary antibody (1: 1,000; His tag antibody) at room temperature for 1 h. After incubation with
primary antibody, the membrane was washed three times (each for 5 min) with TBST buffer. The membrane was then incubated with horseradish peroxidase (HRP) -conjugated rabbit anti-mouse IgG antibodies (1: 5,000 dilution) for 1 h at room temperature. Finally, the membrane was washed three times (each for 5 min) with TBST buffer. The western blot bands were detected by using an electro-chemiluminescence (ECL) western blotting substrate (Millipore, Cat#WBKLS0500) .
Comparing with chFSYRS, chFSYRS V366A variant showed a 9-fold increase in GFP fluorescence incorporated with fluorosulfate-3, 5-difluoro-L-tyrosine, which validate the positive result of the above screening (Figs. 12-13) . Besides, chFSYRS V366A demonstrated enhanced efficiency in incorporating fluorosulfate-2-difluoro-L-tyrosine, fluorosulfate-2, 5-difluoro-L-tyrosine and fluorosulfate-2, 3-difluoro-L-tyrosine, but a decreased efficiency in incorporating fluorosulfate-L-tyrosine and fluorosulfate-3-difluoro-L-tyrosine than chFSYRS. Western blotting analysis of the expression of full length GFP confirm the fluorescence intensity. We proposed that the residue of amino acid in synthetase position 366 is proximal to the meta atom, while fluorine atom is a little larger than hydrogen atom, a minimized residue of alanine will contribute to a lower steric hindrance and methyl group of alanine may have interaction with fluorine, which stabilize the intermediate. Unfortunately, chFSYRS V366A could not mediate the incorporate the fluorosulfate-2, 6-difluoro-L-tyrosine, although this PrUAA is not the one with best proximal reactivity among difluoride added fluorosulfate-L-tyrosine.
Assessment of amber suppression efficiency in mammalian cells
Fluoro substituted fluorosulfate-3, 5-difluoro-L-tyrosine incorporation into proteins in mammalian cells was further tested. The EGFP with TAG mutation at site Y40 was synthesized by (GENWIZ, China) and inserted into pcDNA3.4 vector under the control of CMV, resulting pcDNA3.4-EGFP-Y40TAG as reporter plasmid and suppression of the Y40TAG codon would produce full-length EGFP rendering cells fluorescent. The chimeric synthetases and tRNA genes with codon optimization for human cells were synthesized by (GENWIZ, China) and inserted into pCMV vector by Gibson Assembly under the control of CMV and U6 promoter, resulting, pCMV 8tRNA-chFSYRS and pCMV 8tRNA-chFSYRS V366A, respectively. HEK 293T cells were grown in DMEM medium supplemented with 10%foetal bovine serum and 1%penicillin–streptomycin. Cells were co-transfected with the synthetase plasmids and the reporter plasmid at ratio 1: 1 (μg: μg) . Transfections were performed by PEI according to the manufacturer’s protocol with or without the addition of the corresponding amino acids. Imaging was performed 24 h after transfection. Live HEK 293T cells were imaged XD Inverted Fluorescence Microscope equipped with a 10× objective lens (PlanFluor, SOPTOP) at FITC channel. All images were analysed and processed with ImageJ software (National Institutes of Health) .
Strong EGFP fluorescence was observed from cells transfected with chFSYRS and chFSYRS V366A plasmids and when corresponding UAA was added, which is consistent with the amber suppression result in E. coli. Notably, cell morphology remained normal, which suggest that there is no obvious toxicity of fluoro substituted fluorosulfate-3, 5-difluoro-L-tyrosine to HEK 93T cells, a valuable characteristic of fluoro substituted fluorosulfate-3, 5-difluoro-L-tyrosine possibly due to the extremely low background reactivity of aryl fluorosulfate inside cells. These results demonstrate that fluoro substituted fluorosulfate-3, 5-difluoro-L-tyrosine was incorporated into proteins in mammalian cells using our evolved tRNA synthetase with high efficiency and specificity without causing detrimental effects.
In summary, a series of biorthogonal fluoro substituted fluorosulfate-L-tyrosine with enhanced proximal reactivity and the corresponding tRNA synthetase was developed. Their genetic encoding
capacity was validated in both E. coli and mammalian cells. Since these PrUAA could react with residues of His, Lys and Tyr via SuFEx reaction, which are often found at protein surface and interface, our invention would have broad application in the development of covalent protein drugs.
Example 4
Covalently engineered PD-L1 blocking nanobody (GlueBody) with enhanced T cell activity restoration
Expression and purification of PrUAA incorporated Anti PD-L1 VHH (GlueBody)
Plasmids pBAD-Nb-PD-L1-His (TAGs) were separately co-transform with plasmid pSupAR-chFSYRS or pSupAR-chFSYRS V366A into DH10B competent cells. The transformants were plated on an LB-Ampicillin-Chloramphenicol agar plate and incubated overnight at 37 ℃. A single colony was inoculated into 10 mL of LB medium containing 100 μg/mL Ampicillin and 34 μg/mL Chloramphenicol at 37 ℃. On the following day, 10 mL of overnight cell culture was diluted into 1 L fresh Rich nutrition medium (15 g Na2HPO4·12H2O, 6 g KH2PO4, 20 g Tryptone, 5 g Yeast extracts, 5 g NaCl, 200 mg CaCl2, 200 mg MgCl2, 8 g Glycerol, 0.5 g Glucose) and agitated vigorously at 37 ℃. The bacteria were incubated with 1 mM PrUAA when OD600 reached 0.6 and induced with 0.2%arabinose when OD600 reached 0.8-1.0. After induction of expression at 30℃ for 12 h, bacteria were harvested by centrifugation at 6000 rpm for 30min. Then, resuspending cells with 100 mL binding buffer, (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 20 mM imidazole, lysozyme 1 mg/mL and protease inhibitors) . The cell suspension was sonicated with Sonic Dismembrator (SCIENTZ, 30%output, 30 min, 1 sec off, 1 sec on) in an ice-water bath, followed by centrifugation (15,000 g, 30 min, 4 ℃) . The soluble fractions were collected and loaded onto a pre-packed Ni-NTA column, eluted with NTA 250 buffer (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 250 mM imidazole) followed by further purification on a superdrex 75 column immediately, and stored at -80℃ for future analysis. Molecular weight of the intact wild type and UAA-incorporated proteins were analyzed by a Waters ACQUITY UPLC I-Class SQD 2 MS spectrometer with electrospray ionization (ESI) . LC separation for sortase-mediated protein conjugation was carried out with a BEH300 C4 Acquity column (1.7 μm, 2.1 × 100 mm) , and
positive mode was chosen for ESI-MS to analyze all samples. The total mass of proteins was calculated using MassLynx V4.1 software (Waters) .
ESI-MS analysis showed correct incorporation of four PrUAAs and there is no VHHs with natural amino acids or VHHs with active molecule added detected, which verified the incorporation fidelity and confirmed the biorthogonality of our PrUAAs (Figs. 14A-14D) .
In vitro crosslinking of GlueBodies with PD-L1
The purified GlueBodies was incubated with PD-L1 (Sino Biological, Cat#10084-HNAH) at the molar ratio of 1: 1 in PBS buffer at 37℃ for 5 h. The amount of PD-L1 was 2 μg. 5x reduced loading buffer (CWBio, Cat#CW0027) was added into the tube and heated at 95℃ for 15 min. These samples were then separated by 8-16%SDS-PAGE gel followed by staining with Coomassie brilliant blue. The gray intensity of the band was quantified on ImageJ software.
Since covalent bond cannot be disrupted by denature conditions, SDS-PAGE was used to distinguish the covalent binding and non-covalent binding. The results showed that all the Nb-PD-L1 with PrUAAs at 108 site cross-linked with the target PD-L1 as the new band with molecular weight corresponding to Nb/Ag conjugate was observed on SDS-PAGE. Notably, Nb-PD-L1 with fluorosulfate-2, 5-difluoro-L-tyrosine (28%) and fluorosulfate-2-fluoro-L-tyrosine (26%) showed about 2-fold increasing in the crosslinking ratio in comparison with FSY (15%) , suggesting fluoro addition accelerate the covalent bond formation (Fig. 15) . Notably, although fluorosulfate-3-fluoro-L-tyrosine demonstrate enhanced proximal reactivity than that of fluorosulfate-2-fluoro-L-tyrosine towards electrophilic imidazole, GlueBodies does not behave theoretical covalent binding capacity, which may be resulted from the additional interaction from the introduced fluorine and residues in antigen.
PD-1/PD-L1 blockage assays
To verify that the increased crosslinking will contribute to the enhanced T cell activation restoration, we conducted the following PD-1/PD-L1 blockage assays. PD-1 NFAT-luciferase/Jurkat cells were cultured in RPMI 1640 medium with 10%FBS, 1%Pen-Strep. PD-L1 aAPC/CHO-K1 cells were cultured in Ham’s F-12 with 10%FBS, 1%Penn-Strep (growth medium) . To perform the
blockage assay, PD-L1 aAPC/CHO-K1 cells were seeded at a density of 10,000 cells per well into white 96-well microplate in 100 μL of growth medium. After cell attachment, the medium was removed from the CHO-K1 cells, and cells were incubated with the fresh growth medium supplemented with HBSS, 20 nM GlueBodies for 22 h, followed by washing away the antibody and adding 10,000 PD-1 NFAT-luciferase/Jurkat cells in assay medium (RPMI 1640, 10%FBS, 1%Pen-Strep) with same drugs or control. After 5-6 hours of co-culture, cells were lysed and luciferase assay was performed using Luciferase Reporter Gene Assay Kit (Yeasen, Cat#11401ES76) . Luminescence was measured using a TECAN Spark microplate reader.
The addition of antibodies disrupting PD-1/PD-L1 interactions between the engineered Jurkat cells and CHO-K1 cells would relieve the inhibitory signal and restore T-cell receptor (TCR) signaling. Therefore, CHO-K1 cells were separately treated with GlueBodies or controls. When compared to the non-covalent counterpart, covalently engineered both Nb-PD-L1 L108FSY and Nb-PD-L1 L108m-F FSY showed an enhancement of T-cell activation (Fig. 16) and stronger covalent binding would contribute to a stronger activation as Nb-PD-L1 L108m-F FSY behave better than that of Nb-PD-L1 L108FSY. Traditional antibody binds to the target in a dynamic manner, whereas the dissociation of antibody is not what desired. On the contrary, GlueBody binds to the target irreversibly and accumulation of blocking antibody on cancer cells provided a stronger and more sustainable effect.
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the invention be limited by the specific examples provided within the specification. While the invention has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Furthermore, it shall be understood that all aspects of the invention are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the invention described herein may be
employed in practicing the invention. It is therefore contemplated that the invention shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims (50)
- A compound having the structure (I) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group. - A compound having the structure (II) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group. - The compound of any of claims 1-2, wherein said structure (I) and/or structure (II) is linked to a linkage group R1, said R1 is optionally substituted substitution.
- The compound of claim 3, said R1 is a bond or is selected from group consisting of: -S (O) 2-, -NR1A-, -O-, -S-, -C (O) -, -C (O) NR1A-, -NR1AC (O) -, -NR1AC (O) NR1B-, -C (O) O-, -OC (O) -, optionally substituted alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, and optionally substituted heteroarylene, each said R1A and R1B is independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
- The compound of any of claims 3-4, wherein said linkage group R1 is linked to a linkage group R2, said R2 is optionally substituted substitution.
- The compound of claim 5, said R2 is a bond or is selected from group consisting of: optionally substituted peptidyl moiety, optionally substituted nucleic acid moiety, and optionally substituted carbohydrate moiety.
- The compound of any of claims 5-6, wherein said structure (I) and/or structure (II) is linked to said R2 via optionally substituted tyrosine.
- A compound having the structure (I-A) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group. - A compound having the structure (I-P) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group. - A compound having the structure (II-A) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group. - A compound having the structure (II-P) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group. - The compound of any of claims 1-11, wherein said n is selected from the group consisting of: 1, 2, 3 and 4.
- The compound of any of claims 1-12, wherein said compound having the structure of:
- The compound of any of claims 1-13, wherein said compound having the structure of:
- The compound of any of claims 1-14, wherein said compound having the structure of:
- A compound having the structure of: wherein, said X is selected from the electron-withdrawing group.
- A compound having the structure of: wherein, said X is selected from the electron-withdrawing group.
- The compound of any of claims 1-17, wherein each of said X is independently halogen.
- The compound of any of claims 1-18, wherein each of said X is independently F.
- A protein comprising the structure of the compound of any of claims 1-19.
- A protein comprising an unnatural amino acid having the structure (I) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group. - The protein of any of claims 20-21, wherein said protein comprises an unnatural amino acid having the structure of the compound of any of claims 1-19.
- The protein of any of claims 20-22, wherein said protein is derived from antigen-binding protein or the fragment thereof.
- The protein of any of claims 21-23, wherein said protein comprises said unnatural amino acid at position 108 as set forth in sequence of PD-L1 binding protein or the fragment thereof.
- The protein of any of claims 21-24, wherein said protein comprises said unnatural amino acid at position 108 as set forth in sequence of anti-PD-L1 nanobody or the fragment thereof.
- The protein of any of claims 21-25, wherein said protein comprises said unnatural amino acid at position 108 as set forth in sequence of SEQ ID NO: 1.
- The protein of any of claims 20-26, wherein said protein further comprises proteolysis targeting moiety.
- The protein of any of claims 20-27, wherein said protein further comprises mannose-6-phosphate, N-acetylgalactosamine (GalNAc) , cell-penetrating peptide and/or lysosome-sorting sequence.
- A nucleic acid comprising a sequence encoding the protein of any of claims 20-28.
- A synthetase comprising a mutant at position 366 and/or position 367 as set forth in sequence of SEQ ID NO: 29.
- A synthetase comprising an alanine at position 366 and/or position 367 as set forth in sequence of SEQ ID NO: 29.
- A synthetase comprising a sequence of SEQ ID NO: 31 and/or 34.
- A nucleic acid comprising a sequence encoding the synthetase of any of claims 30-32.
- A nucleic acid comprising a sequence of SEQ ID NO: 30 and/or 33.
- A vector comprising the nucleic acid of any of claims 29 and 33-34.
- A combination comprising the synthetase of any of claims 30-32 and the compound of any of claims 1-19.
- A method of preparing the protein of any of claims 20-28, wherein said method comprises providing the synthetase of any of claims 30-32, the compound of any of claims 1-19 and/or the combination of claim 36.
- A cell comprising the compound of any of claims 1-19, the protein of any of claims 20-28, the nucleic acid of any of claims 29 and 33-34, the synthetase of any of claims 30-32, the nucleic acid of any of claims 29 and 33-34, the vector of claim 35, and/or the combination of claim 36.
- A composition comprising the compound of any of claims 1-19, the protein of any of claims 20-28, the nucleic acid of any of claims 29 and 33-34, the synthetase of any of claims 30-32, the nucleic acid of any of claims 29 and 33-34, the vector of claim 35, the combination of claim 36 and/or the cell of claim 38, and optionally a pharmaceutically acceptable adjuvant.
- A kit comprising the compound of any of claims 1-19, the protein of any of claims 20-28, the nucleic acid of any of claims 29 and 33-34, the synthetase of any of claims 30-32, the nucleic acid of any of claims 29 and 33-34, the vector of claim 35, the combination of claim 36, the cell of claim 38, and/or the composition of claim 39.
- A method for inhibiting binding of a PD-L1 protein to a PD-L1 ligand, wherein said method comprises providing the compound of any of claims 1-19, the protein of any of claims 20-28, the nucleic acid of any of claims 29 and 33-34, the synthetase of any of claims 30-32, the nucleic acid of any of claims 29 and 33-34, the vector of claim 35, the combination of claim 36, the cell of claim 38, the composition of claim 39, and/or the kit of claim 40.
- A method for activating immune cell, wherein said method comprises providing the compound of any of claims 1-19, the protein of any of claims 20-28, the nucleic acid of any of claims 29 and 33-34, the synthetase of any of claims 30-32, the nucleic acid of any of claims 29 and 33-34, the vector of claim 35, the combination of claim 36, the cell of claim 38, the composition of claim 39, and/or the kit of claim 40.
- The method of claim 42, wherein said immune cell comprises T cell.
- The method of any of claims 42-43, wherein said activating is tested via luciferase assay.
- A method of preparing a compound having the structure (M) of:
wherein, said n is more than 0, and X is selected from the electron-withdrawing group; wherein said method comprises providing a ligase comprising sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 25, and SEQ ID NO: 27. - The method of claim 45, wherein said method comprises providing a tyrosine phenol lyase encoded by sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 20, SEQ ID NO: 24, and SEQ ID NO: 26.
- The method of any of claims 45-46, wherein said n is selected from the group consisting of: 1, 2, 3 and 4.
- The method of any of claims 45-47, wherein said compound comprises the structure of:
- The method of any of claims 45-48, wherein each of said X is independently halogen.
- The method of any of claims 45-49, wherein each of said X is independently F.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202380009507.0A CN117279889A (en) | 2022-04-28 | 2023-04-27 | Substituted fluorosulfates and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2022089722 | 2022-04-28 | ||
CNPCT/CN2022/089722 | 2022-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023208081A1 true WO2023208081A1 (en) | 2023-11-02 |
Family
ID=88517850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/091020 WO2023208081A1 (en) | 2022-04-28 | 2023-04-27 | Substituted fluorosulfate and use thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117279889A (en) |
WO (1) | WO2023208081A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019173760A1 (en) * | 2018-03-08 | 2019-09-12 | The Regents Of The University Of California | Bioreactive compositions and methods of use thereof |
CN112028987A (en) * | 2020-06-01 | 2020-12-04 | 广东圣赛生物科技有限公司 | Protein medicine combined with immunosuppressive molecule PD-L1 |
WO2021102624A1 (en) * | 2019-11-25 | 2021-06-03 | Hangzhou Branch Of Technical Institute Of Physics And Chemistry, Chinese Academy Of Sciences | Covalent protein drugs developed via proximity-enabled reactive therapeutics (perx) |
CN113699124A (en) * | 2021-09-08 | 2021-11-26 | 北京大学 | Preparation method of protein containing non-natural amino acid |
EP3964570A1 (en) * | 2019-04-30 | 2022-03-09 | Suzhou Kunpeng Biotech Co., Ltd. | Aminoacyl-trna synthetase efficiently introducing lysine derivatives |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100286112A1 (en) * | 2007-09-10 | 2010-11-11 | Oscar Barba | Compounds for the treatment of metabolic disorders |
GB0904284D0 (en) * | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
CN102946882B (en) * | 2010-02-02 | 2016-05-18 | 格斯有限公司 | Phenylalamine derivatives and as the purposes of non-peptide GLP-1-1 receptor modulators |
NZ710034A (en) * | 2013-03-14 | 2020-06-26 | Boehringer Ingelheim Int | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
WO2020127685A1 (en) * | 2018-12-19 | 2020-06-25 | Leo Pharma A/S | Amino-acid anilides as small molecule modulators of il-17 |
EP3935051A1 (en) * | 2019-03-08 | 2022-01-12 | Leo Pharma A/S | Small molecule modulators of il-17 |
-
2023
- 2023-04-27 WO PCT/CN2023/091020 patent/WO2023208081A1/en active Application Filing
- 2023-04-27 CN CN202380009507.0A patent/CN117279889A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019173760A1 (en) * | 2018-03-08 | 2019-09-12 | The Regents Of The University Of California | Bioreactive compositions and methods of use thereof |
EP3964570A1 (en) * | 2019-04-30 | 2022-03-09 | Suzhou Kunpeng Biotech Co., Ltd. | Aminoacyl-trna synthetase efficiently introducing lysine derivatives |
WO2021102624A1 (en) * | 2019-11-25 | 2021-06-03 | Hangzhou Branch Of Technical Institute Of Physics And Chemistry, Chinese Academy Of Sciences | Covalent protein drugs developed via proximity-enabled reactive therapeutics (perx) |
CN112028987A (en) * | 2020-06-01 | 2020-12-04 | 广东圣赛生物科技有限公司 | Protein medicine combined with immunosuppressive molecule PD-L1 |
CN113699124A (en) * | 2021-09-08 | 2021-11-26 | 北京大学 | Preparation method of protein containing non-natural amino acid |
Non-Patent Citations (4)
Title |
---|
GUOSI LI; JIAZHANG LIAN; HAILONG XUE; YIQI JIANG; SHUYUN JU; MIANBIN WU; JIANPING LIN; LIRONG YANG: "Biocascade Synthesis of L‐Tyrosine Derivatives by Coupling a Thermophilic Tyrosine Phenol‐Lyase and L‐Lactate Oxidase", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, WILEY-VCH, DE, vol. 2020, no. 8, 18 February 2020 (2020-02-18), DE , pages 1050 - 1054, XP072121588, ISSN: 1434-193X, DOI: 10.1002/ejoc.202000061 * |
KIM MIN PYEONG, CHO HOJIN, KAYAL SWATILEKHA, JEON MIN HO, SEO JEONG KON, SON JEONGMIN, JEONG JINSIL, HONG SUNG YOU, CHUN JOONG-HYU: "Direct 18 F-Fluorosulfurylation of Phenols and Amines Using an [ 18 F]FSO 2 + Transfer Agent Generated In Situ", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 88, no. 9, 5 May 2023 (2023-05-05), pages 6263 - 6273, XP093102684, ISSN: 0022-3263, DOI: 10.1021/acs.joc.3c00512 * |
NAGASAWA TORU, UTAGAWA TAKASHI, GOTO JOJI, KIM CHAN-JO, TANI YOSHIKI, KUMAGAI HIDEHIKO, YAMADA HIDEAKI: "Syntheses of l-Tyrosine-Related Amino Acids by Tyrosine Phenol-lyase of Citrobacter intermedius", EUROPEAN JOURNAL OF BIOCHEMISTRY, PUBLISHED BY SPRINGER-VERLAG ON BEHALF OF THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES, vol. 117, no. 1, 1 June 1981 (1981-06-01), pages 33 - 40, XP093095163, ISSN: 0014-2956, DOI: 10.1111/j.1432-1033.1981.tb06299.x * |
WANG, NANXI, ET AL.: "Genetically Encoding Fluorosulfate‑L‑tyrosine To React with Lysine, Histidine, and Tyrosine via SuFEx in Proteins in Vivo", J. AM. CHEM. SOC., vol. 140, 30 March 2018 (2018-03-30), XP055816028, DOI: 10.1021/jacs.8b01087 * |
Also Published As
Publication number | Publication date |
---|---|
CN117279889A (en) | 2023-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6321658B2 (en) | Amino acid derivatives | |
JP5605602B2 (en) | Method for synthesizing cyclic peptide compound | |
US8986953B2 (en) | Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation | |
US20170152287A1 (en) | Methods and compositions for site-specific labeling of peptides and proteins | |
CA2918064C (en) | Amino acid derivatives | |
Zambaldo et al. | An orthogonal seryl-tRNA synthetase/tRNA pair for noncanonical amino acid mutagenesis in Escherichia coli | |
WO2023208081A1 (en) | Substituted fluorosulfate and use thereof | |
EP3024823B1 (en) | Intercalating amino acids | |
JP7093300B2 (en) | Ribosome display complex and its manufacturing method | |
JP7461652B2 (en) | Compound library and method for producing the compound library | |
Bionda et al. | Ribosomal synthesis of thioether-bridged bicyclic peptides | |
US20230139680A1 (en) | A genetically encoded, phage-displayed cyclic peptide library and methods of making the same | |
CN109180691B (en) | C3-aromatic pyrroloindole alkaloid and synthetic method thereof | |
WO2018148754A1 (en) | Site-specific generation of phosphorylated tyrosines in proteins | |
US9823254B2 (en) | Reversible chemoenzymatic labeling of native and fusion carrier protein motifs | |
JP2011239686A (en) | Method of producing peptide and peptide derivative | |
WO2023068296A1 (en) | Method for producing compounds, method for producing compound library, compound library, and screening method | |
CN117730076A (en) | Amino acids containing tetrazine moieties | |
Halonski | Utilization of Unnatural Amino Acids to Modulate Protein Structure and Function | |
Middel | Photocleavable Templates for PNA Base Pairing Mediated Native Chemical Ligation | |
Michels | Precision crosslinking and active-site modifications via site-specific protein engineering | |
Murakami et al. | High-affinity mirror-image monobody targeting MCP-1 generated via TRAP display and chemical protein synthesis | |
CN117292741A (en) | Method for developing cell membrane-binding and/or serum albumin lipidation analogues by using computer aided design and application | |
KR101223664B1 (en) | Method for preparing a carboxylic acid using nitrilase RMN1 | |
KR101223666B1 (en) | Method for preparing a carboxylic acid using nitrilase ORN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 202380009507.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23795513 Country of ref document: EP Kind code of ref document: A1 |